Safety and Targeting of Anti-hk2 Antibody in mCRPC
Conditions: Castration-Resistant Prostatic Cancer; Metastatic Disease Intervention: Drug: 111In-DOTA-h11B6 Sponsors: Tomopath Inc.; Invicro; Janssen Research & Development, LLC Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials